Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis

Criado, Paulo Ricardo; Pincelli, Thais; Criado, Roberta F. J.

doi:10.1111/ijd.14994

Cited by 13 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the LIBERTY AD CAFÉ trial evaluated dupilumab 300 mg administered weekly or fortnightly to adults with an inadequate not an indication for dupilumab. Published clinical cases and the case series (Table 1) bring together 118 patients diagnosed with chronic prurigo nodularis [77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96] and include patients with and without a history of atopy. Only one involved a child.…”

Section: Approved Indications For Dupilumabmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

show abstract

Section: Approved Indications For Dupilumabmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…Similarly, a substantial change in prurigo phenotype was noted after 16 weeks of therapy with dupilumab (p < 0.0001) and lasted until week 52 [21]. Also, several retrospective studies have reported the efficacy of dupilumab on prurigo nodularis [24,25].…”

Section: Prurigo Nodularismentioning

confidence: 87%

“…Among the included 7 articles, 6 studies retrospective design and one study randomized controlled trail [21][22][23][24][25][26][27]. Furthermore, 3 of the articles were published in the America [22,26,27], 2 articles were published in Italy [21,23], one article was published in Europe and one article was published in Australia [24,25]. The sample size ranged from 16 to 1491 patients, with a total of 2349 patients involved in the current systematic review and the age of the patients was 18 to 87 years.…”

Section: Baseline Characteristics Studymentioning

confidence: 99%

“…Most of the included studies demonstrated that the dupilumab has been shown to rapidly improving signs and symptoms in the treatment of extreme AD [21][22][23]26,27], including skin manifestations such as pruritus, lichenification, prurigo nodularis, excoriation, erythema and as well as sleep disruptions, edema/population and the overall quality of life of patients. Dupilumab is also well tolerated, with few adverse effects, including reactions at the injection site, conjunctivitis, nasopharyngitis, etc [25].…”

Section: Quality Of Lifementioning

confidence: 99%

See 1 more Smart Citation

Untitled

2022

CDT

View full text Add to dashboard Cite

Background: The Atopic Dermatitis (AD) is a chronic, pruritusinflammatory TH2dominant skin disorder characterized by a reaction with complex immunopathogenesis. Dupilumab's effectiveness and safety profile by phenotypic variations of atopic dermatitis the treatment of atopic dermatitis has been investigated in a variety of large clinical trials in atopic dermatitis for more than 10 years. The goal of the current systematic review was to determine the effectiveness and protection of dupilumab through phenotypic differences in atopic dermatitis. Methods:We systematically searched PubMed, MEDLINE, EMBASE and Google scholar databases to find appropriate articles published between last ten years related to dupilumab efficacy and safety by phenotypic variations of atopic dermatitis with the appropriate key terms (MeSH) including "dupilumab", "atopic dermatitis", "eczema", "phenotypic variations" "phenotypes" etc.

show abstract

“…25 Preliminary success of dupilumab was reported in 6 case reports, 5 case series and one multicenter cohort study of 16 patients. 50 -59 Overall, data demonstrated reduction in number, size, erythema of PN nodules and itch. 25 Two clinical trials evaluating the use of dupilumab in PN, are currently in the recruitment phase (PRIME and PRIME2; NCT04183335, and NCT04202679).…”

Section: Introductionmentioning

confidence: 96%

Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis

et al. 2021

View full text Add to dashboard Cite

Type 2 immunity, illustrated by T helper 2 lymphocytes (Th2) and downstream cytokines (IL-4, IL-13, IL-31) as well as group 2 innate lymphoid cells (ILC2), is important in host defense and wound healing. 1 The hallmark of type 2 inflammation is eosinophilia and/or high IgE counts and is best recognized in atopic diathesis. Persistent eosinophilia, such as seen in hypereosinophilic syndromes, leads to fibrosis and hence therapeutic Type 2 inhibition in fibrotic diseases is of high interest. Furthermore, as demonstrated in cutaneous T cell lymphoma, advanced disease is characterized by Th1 to Th2 switch allowing cancer progression and immunosuppression. Development of targeted monoclonal antibodies against IL-4Rα (eg, dupilumab) led to a paradigm shift for the treatment of atopic dermatitis (AD) and stimulated research to better understand the role of Type 2 inflammation in other skin conditions. In this review, we summarize up to date knowledge on the role of Type 2 inflammation in skin diseases other than AD and highlight whether the use of Type 2 targeted therapies has been documented or is being investigated in clinical trials. This manuscript reviews the role of Type 2 inflammation in dermatitis, neurodermatitis, IgE-mediated dermatoses (eg, bullous pemphigoid, chronic spontaneous urticaria), sclerodermoid conditions and skin neoplasms.

show abstract

Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis

Cited by 13 publications

References 5 publications

Dupilumab: A Review of Present Indications and Off-Label Uses

Dupilumab: A Review of Present Indications and Off-Label Uses

Untitled

Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis

Contact Info

Product

Resources

About